| Rivaroxaban in the contemporary treatment of acute coronary syndromes. | |
| | |
MedLine Citation:
|
PMID: 21554163 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Introduction: Rivaroxaban is the first orally bioavailable direct factor Xa inhibitor and its role in acute coronary syndrome is not fully understood. A significant residual risk of recurrent ischemia remains in patients with acute coronary syndrome despite optimal medical therapy. Warfarin has demonstrated modest benefit that is offset by the risk of bleeding and complexity in its management. Rivaroxaban may be an attractive agent for the treatment of acute coronary syndromes given its predictable pharmacodynamics and favorable safety profile. Areas covered: The current guideline-based antithrombotic and adjunctive medical therapies in acute coronary syndrome are summarized in this review. Rivaroxaban's drug profile, its current applications, ongoing trials and experience in patients with acute coronary syndrome are also described. Expert opinion: Current experience of rivaroxaban in acute coronary syndrome demonstrates its safety and a trend towards benefit when added to current optimal medical therapy. The benefits were observed primarily in patients receiving aspirin monotherapy and increased bleeding among those receiving dual anti-platelet therapy. This suggests that there may be a narrow window between the optimal clinically achievable antithrombotic effect and the point where bleeding risk outweighs the benefits. Though promising, it remains to be seen if this drug will achieve the right balance between efficacy and bleeding risk. |
| | |
Authors:
|
Deepu Alexander; Allen Jeremias |
Related Documents
:
|
18558443 - In response to article entitled "coronary spasm and hypersensitivity to amoxicillin: ko... 17360053 - Kounis syndrome secondary to amoxicillin/clavulanic acid use. 18926373 - Variant angina in an adolescent coexisting with intermittent wolff-parkinson-white synd... |
Publication Detail:
|
Type: Journal Article Date: 2011-05-10 |
Journal Detail:
|
Title: Expert opinion on investigational drugs Volume: 20 ISSN: 1744-7658 ISO Abbreviation: Expert Opin Investig Drugs Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-05-11 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9434197 Medline TA: Expert Opin Investig Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 849-57 Citation Subset: IM |
Affiliation:
|
State University of New York-Stony Brook School of Medicine, Health Sciences Centre Division of Cardiovascular Medicine , T16-080, Stony Brook, NY 11794 , USA +1 631 444 1064 ; +1 631 444 1054 ; allen.jeremias@stonybrook.edu. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.
Next Document: Helicobacter pylori and risk of upper gastrointestinal bleeding among users of selective serotonin r...